Cleara, under the guidance of Peter de Keizer, is a biopharmaceutical R&D company dedicated to discovery and development of therapies against cancer and chronic diseases through selective elimination of subtypes of cellular senescence. Cleara has optimized two lead development candidates, CL04177 and CL04183 that are specifically able to eliminate a type called “scarred” senescence, found in several chronic diseases and late-stage cancer in humans.